Articles
Dissecting PhRMA's Opposition to H.R. 3 Lower Drug Costs Now Act of 2019
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.
Originally published
on 10/11/2019
in
STAT News
The bill, if passed, would allow Medicare to negotiate drug prices using 120% of international reference price as the payment upper limit.
Dr. Peter Bach responds to PhRMA's strong stance in opposition to H.R. 3 Lower Drug Costs Now Act of 2019. PhRMA neglects to address the pharmaceutical market as a global market in widely circulated talking points, and a deeper analysis proves claims made from the data to be misleading.
Read the full editorial here.
Share